COMMUNIQUÉS West-GlobeNewswire

-
Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019
23/09/2019 -
First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference
23/09/2019 -
TG Therapeutics Announces Data Presentations at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
23/09/2019 -
ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference
23/09/2019 -
BioCryst Appoints Helen Thackray, M.D., to Board of Directors
23/09/2019 -
Athenex Completes Construction of New API Facility in Chongqing
23/09/2019 -
Athenex to Present at the 2019 San Antonio Breast Cancer Symposium
23/09/2019 -
Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019
23/09/2019 -
Akcea Announces CEO Transition and Elects Two New Board Members
23/09/2019 -
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy
23/09/2019 -
Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
23/09/2019 -
ReWalk Robotics to Present at the Sidoti & Company Conference on September 25th
23/09/2019 -
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference
23/09/2019 -
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
23/09/2019 -
Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies
23/09/2019 -
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
23/09/2019 -
Cambrex Corporation Announces Expiration of “Go Shop” Period Under Merger Agreement
23/09/2019 -
Precision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer
23/09/2019 -
Plus Therapeutics to Receive $4.6MM Reimbursement Payment
23/09/2019
Pages